Patents Examined by Brad Duffy
  • Anti-FcRH5 antibodies and immunoconjugates and methods of use
    Patent number: 9360484
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: June 7, 2016
    Assignee: GENENTECH, INC.
    Inventors: Kristi Elkins, Andrew Polson, Allen Ebens, Camelia Adams, Bing Zheng, Jagath R. Junutula, Jo-Anne Hongo, Yan Wu
  • CD37-binding molecules and immunoconjugates thereof
    Patent number: 9346887
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: May 24, 2016
    Assignee: ImmunoGen, Inc.
    Inventors: Jutta Deckert, Peter Park, Daniel Tavares, Lingyun Rui
  • Humanized anti-CDCP1 antibodies
    Patent number: 9346886
    Abstract: The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: May 24, 2016
    Assignee: Roche Glycart AG
    Inventors: Johannes Auer, Birgit Bossenmaier, Guy Georges, Alexander Lifke, Ekkehard Moessner, Gerhard Niederfellner
  • Anti-AXL antibody
    Patent number: 9340615
    Abstract: An objective of the present invention is to decrease the immunogenicity of mouse-derived anti-AXL antibodies in humans by humanizing them. The present invention provides antibodies that can bind to a specific region in Anexelekto (AXL) and humanized antibodies that are produced based on such antibodies. The anti-AXL antibodies of the present invention have high antitumor activity, and are useful as agents for decreasing the AXL expression level, antitumor agents, and diagnostic agents for cancer.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: May 17, 2016
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Atsuhiko Maeda, Hajime Miyamoto, Taichi Kuramochi, Atsushi Matsuo, Tomoyuki Igawa, Hirotake Shiraiwa, Hiroyuki Tsunoda, Tatsuhiko Tachibana
  • Methods for measuring carcinoembryonic antigen
    Patent number: 9341628
    Abstract: Disclosed herein are methods of accurately measuring carcinoembryonic antigen in a biological sample and methods of identifying and treating a mucinous cyst in a subject.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: May 17, 2016
    Assignee: INTERPACE DIAGNOSTICS CORPORATION
    Inventors: Sydney David Finkelstein, Sara Ann Jackson, Jamie Michelle Bleicher, Eric Matthew Gayle Ellsworth, Dennis Morgan Smith, Jr.
  • Methods for treating neoplasia
    Patent number: 9328161
    Abstract: The invention provides therapeutic methods featuring the use of chimeric human/mouse antibodies for the treatment of neoplasia.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: May 3, 2016
    Assignee: ZESTAGEN S.A.
    Inventors: Katerina Sidera, Avgi Mamalaki, Evangelia Patsavoudi
  • Modulators and methods of use
    Patent number: 9320812
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of such modulators to treat hyperproliferative disorders are provided.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: April 26, 2016
    Assignee: Stemcentrx, Inc.
    Inventors: Johannes Hampl, Scott J. Dylla, Orit Foord, Robert A. Stull
  • Antibodies for treatment of cancer
    Patent number: 9321842
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: April 26, 2016
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITAT MAINZ
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, Michael Weichel
  • Stable and soluble antibodies inhibiting TNF alpha
    Patent number: 9315572
    Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF?, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF?, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF?-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: April 19, 2016
    Assignee: ESBATech, an Alcon Biomedical Research, Unit LLC
    Inventors: Stefan Ewert, Alcide Barberis, David M. Urech, Adrian Auf Der Maur, Peter Lichtlen
  • Detection and treatment of cancer
    Patent number: 9310371
    Abstract: The present invention relates to a method for diagnosing, evaluating the prognosis of a cancer patient and evaluating the aggressiveness of a cancer. The methods comprise detecting the phosphorylation status of a Scribble protein, a fragment or variant thereof, wherein the phosphorylation status is indicative of cancer, prognosis and the aggressiveness of a cancer. In one embodiment the cancer is breast cancer.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: April 12, 2016
    Assignee: University of Essex Enterprises Ltd.
    Inventor: Metodi Vladimirov Metodiev
  • Antibodies and methods of use thereof
    Patent number: 9309325
    Abstract: The disclosure relates to protease-binding agent specific for a protease. The agent may be an antibody capable of specifically binding and inhibiting a protease, such as a P1-Arg-specific protease. The disclosure also provides methods of producing, and compositions comprising the subject agent. Methods and kits related to the protease-binding agent find use in protection against, detection, diagnosing, treating cancer and infections due to pathogens containing active proteases.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: April 12, 2016
    Assignee: The Regents of the University of California
    Inventors: Charles S. Craik, Eric L. Schneider
  • Dual specificity antibody fusions
    Patent number: 9309327
    Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab? fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: April 12, 2016
    Assignee: UCB Pharma S.A.
    Inventors: David Paul Humphreys, Emma Dave, Laura Griffin, Sam Philip Heywood
  • Fibronectin-based binding molecules and uses thereof
    Patent number: 9296810
    Abstract: The invention provides fibronectin type III (Fn3)-based binding molecules that bind to a specific target antigen. The invention further provides bispecific Fn3-based binding molecules that bind to two or more targets simultaneously. The Fn3-based binding molecules of the invention can also be linked together to form multispecific Fn3-based binding molecules, and/or can be conjugated to a non-Fn3 moiety, such as, Human Serum Albumin (HSA), for improved half life and stability. The invention also provides methods for generating, screening and using Fn3-based binding molecules in a variety of therapeutic and diagnostic applications.
    Type: Grant
    Filed: May 4, 2009
    Date of Patent: March 29, 2016
    Assignee: NOVARTIS AG
    Inventors: John Hastewell, Andreas Loew
  • Covalent diabodies and uses thereof
    Patent number: 9296816
    Abstract: The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: March 29, 2016
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang
  • Antibodies to EphA3
    Patent number: 9290571
    Abstract: The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Grant
    Filed: December 30, 2013
    Date of Patent: March 22, 2016
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Kenneth Luehrsen, David Martinez, Christina Yi, Christopher R. Bebbington, Geoffrey T. Yarranton
  • Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
    Patent number: 9283276
    Abstract: The present invention relates to antibodies, particularly antibody 175, and fragments thereof or antibodies derived therefrom, which bind to the EGF receptor, particularly to amplified or overexpressed epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. These antibodies are useful in the diagnosis and treatment of cancer. Recombinant or hybrid antibodies having the variable region heavy or light chain sequence(s) of antibody 175 are also provided. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: March 15, 2016
    Assignee: Ludwig Institute for Cancer Research Ltd.
    Inventors: Terrance Grant Johns, Elizabeth Stockert, Stephen Stockert, Lloyd J. Old, Andrew M. Scott, Veronika M. Rayzman
  • Covalent diabodies and uses thereof
    Patent number: 9284375
    Abstract: The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: March 15, 2016
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang
  • Antibodies
    Patent number: 9284376
    Abstract: The present invention relates to the use of VEGF antagonists and a novel anti-?5?1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-?5?1 antibodies and methods of making and using them.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: March 15, 2016
    Assignee: Genentech, Inc.
    Inventors: Wei-Ching Liang, Gregory D. Plowman, Yan Wu, Weilan Ye
  • FGFR4 antibodies
    Patent number: 9284379
    Abstract: The present invention relates to FGFR4 antibodies including fragments or derivatives thereof and the polynucleotides encoding the antibodies. Expression vectors and host cells comprising the polynucleotides are provided. Further, the invention refers to pharmaceutical compositions comprising the FGFR4 antibodies and methods for the treatment, prevention or diagnosis of disorders associated with FGFR4 expression.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: March 15, 2016
    Assignee: U3 Pharma GmbH
    Inventors: Johannes Bange, Jens Niewoehner, Patricia Aus Dem Siepen, Mike Rothe
  • Neuregulin-1-based prognosis and therapeutic stratification of colorectal cancer
    Patent number: 9279812
    Abstract: The present invention relates to the prognosis, therapeutic stratification and treatment of colorectal cancer. More in particular, the present invention discloses that significantly increased levels of transmembrane type 1 neuregulin-1 in tumor-associated mesenchymal cells present in a sample of a patient indicate that the patient has a worse prognosis when compared to patients having low levels of transmembrane type 1 neuregulin-1 in tumor-associated mesenchymal cells. Moreover, the present invention relates to the usage of transmembrane type 1 neuregulin-1 expression in tumor-associated mesenchymal cells to predict resistance to HER1 inhibitors during colorectal cancer therapy and/or to predict whether a patient would benefit from a therapy based on the prevention of neuregulin-1 and/or HER3 activity.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: March 8, 2016
    Assignee: UNIVERSITEIT GENT
    Inventors: Olivier De Wever, Astrid De Boeck